☰

Carol E. O'Hear, Ph.D. - Publications

Affiliations: 
2004 University of Washington, Seattle, Seattle, WA 
Area:
Molecular Biology, Pharmacy, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Hamid O, Molinero L, Bolen CR, Sosman JA, Muñoz-Couselo E, Kluger HM, McDermott DF, Powderly J, Sarkar I, Ballinger M, Fassò M, O'Hear C, Chen DS, Hegde PS, Hodi FS. Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358540 DOI: 10.1158/1078-0432.Ccr-18-3488  0.447
2019 Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecologic Oncology. PMID 31204078 DOI: 10.1016/J.Ygyno.2019.05.021  0.308
2018 Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. Jama Oncology. PMID 30242306 DOI: 10.1001/Jamaoncol.2018.4224  0.32
2018 Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer (Oxford, England : 1990). 101: 201-209. PMID 30077125 DOI: 10.1016/J.Ejca.2018.06.031  0.344
2018 Kim JW, Shaffer DR, Massard C, Powles T, Harshman LC, Braiteh FS, Conkling PR, Sarkar I, Kadel EE, Mariathasan S, O'Hear C, Schiff C, Fasso M, Carroll S, Petrylak DP. A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: 187-187. DOI: 10.1200/Jco.2018.36.6_Suppl.187  0.303
2018 Kim D, Gadgeel SM, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A, Heist RS, Wozniak AJ, Hernandez G, Sarkar I, Mitry E, Foster P, O'Hear C, et al. Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). Journal of Clinical Oncology. 36: 9009-9009. DOI: 10.1200/Jco.2018.36.15_Suppl.9009  0.345
2018 Molinero L, Chang C, Udyavar A, Fasso M, O'Hear C, Emens L, Cruz C, Hegde P, Schmid P. Abstract P2-09-13: Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-13  0.324
2017 Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Morales R, Burris HA, Kim JW, Ding B, Chang D, Fasso M, O'Hear C, Vogelzang NJ. Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. Journal of Clinical Oncology. 35: 290-290. DOI: 10.1200/Jco.2017.35.6_Suppl.290  0.33
2017 Fleming GF, Emens LA, Eder JP, Hamilton EP, Liu JF, Liu B, Molinero L, Fasso M, O'Hear C, Braiteh FS. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). Journal of Clinical Oncology. 35: 5585-5585. DOI: 10.1200/Jco.2017.35.15_Suppl.5585  0.313
2016 Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T, Van Der Heijden MS, Fasso M, O'Hear C, Ballinger M, Fine GD, Sandler A, Chen DS, et al. Association of PD-L2 expression in human tumors with atezolizumab activity. Journal of Clinical Oncology. 34: 11506-11506. DOI: 10.1200/Jco.2016.34.15_Suppl.11506  0.408
2015 Powles T, Nickles D, Allen EV, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake CG, O'Hear C, et al. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) Journal For Immunotherapy of Cancer. 3: 83. DOI: 10.1186/2051-1426-3-S2-P83  0.333
2010 O'Hear C, Foote J. Antibody buffering of systemically administered lysozyme. European Journal of Haematology. 84: 252-8. PMID 19922461 DOI: 10.1111/J.1600-0609.2009.01383.X  0.675
2006 O'Hear C, Foote J. Antibody buffering in the brain. Journal of Molecular Biology. 364: 1003-9. PMID 17045608 DOI: 10.1016/J.Jmb.2006.09.029  0.702
2005 O'Hear CE, Foote J. Antibody buffering of a ligand in vivo. Proceedings of the National Academy of Sciences of the United States of America. 102: 40-4. PMID 15615858 DOI: 10.1073/pnas.0405797102  0.712
2004 O'Hear CE, Foote J. 217 ANTIBODY BUFFERING: A NOVEL METHOD OF DRUG DELIVERY. Journal of Investigative Medicine. 52: S117.2-S117. DOI: 10.1136/jim-52-suppl1-217  0.704
2004 OʼHear CE, Foote J. ANTIBODY BUFFERING: A NOVEL METHOD OF DRUG DELIVERY. Journal of Investigative Medicine. 52: S117. DOI: 10.1097/00042871-200401001-00217  0.704
Show low-probability matches.